FDA approves IV maintenance dosing of Leqembi® for the treatment of early Alzheimer's Disease in the US
Veröffentlicht: 07.08.2025 um 18:06 Uhr, prnewswire.co.uk
View original content:https://www.prnewswire.co.uk/news-releases/fda-approves-iv-maintenance-dosing-of-leqembi-lecanemab-irmb-for-the-treatment-of-early-alzheimers-disease-in-the-us-302360423.html
en | boerse | 67950571 |
